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1015-9584/Copyright ª 2015, Asian SuSummary Objective: This study was conducted to identify the safety measures of perform-
ing clean urologic operations without administration of prophylaxis antibiotics.
Methods: We conducted a double-blind randomized controlled trial with patients who under-
went clean urologic operations in Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from April
2013 to January 2014. The local and systemic infection states were compared between the pro-
phylaxis and placebo groups. Local infection was identified as surgical site infection and sys-
temic infection as fever and leukocytosis.
Results: A total of 42 patients participated in the study (21 patients in each group), comprising 14
(33.3%) children and 28 (66.7%) adults. The most frequently performed operation was surgical
sperm retrieval. No patients in either groupwere found to have local or systemic infection. How-
ever, there was a statistical difference in the white blood cell counts between the two groups
(pZ 0.003), although there was no sign of local or systemic infection in any of the patients.
Conclusion: Clean urologic operations without prophylaxis antibiotic therapy can be safely
applied to urologic patients.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.have no financial or nonfinancial conflicts of interest.
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Safety of clean urologic operations 2251. Introduction
The introduction of prophylaxis antibiotics is a procedure
that involves the administration of antibiotics shortly
before or at the beginning of an operation or intervention
procedure in order to reduce the risk of postoperative
infection.1,2 Postoperative infection can be localized or
systemic.2,3 The benefit and safety of prophylaxis antibi-
otics depend on the patient’s characteristics, type of
operation, and potential morbidity after the operation.
Thus, prophylaxis antibiotics are recommended if the
benefits outweigh the risk involved and the costs
incurred.2,4
Similar to other surgical procedures, urologic operations
can be categorized into four types: clean, clean-
contaminated, contaminated, and dirty operations.5 Clean
urologic operations are defined as operations performed in
uninfected areas with no involvement of the urinary tract,
and primary closure is established after the operation.1,6,7
International urology associations, such as the European
Association of Urology (EAU) and the American Urological
Association (AUA), are in favor of prophylaxis antibiotic
therapy in those specified categories of operations.2,3 In
clean operations, prophylaxis antibiotic therapy is only
recommended for patients with risk factors associated with
immunosuppression state. Meanwhile, prophylaxis antibi-
otic therapy is recommended for all clean-contaminated,
contaminated, and dirty operations.2,3,6 Furthermore,
prophylaxis antibiotics should not be given to those un-
dergoing clean urologic operations without prior determi-
nation of risk factors. Sterilization of the operating theater
and instruments as well as adequate aseptic and antiseptic
techniques are sufficient to prevent postoperative in-
fections associated with clean urologic operations.2,7,8 The
aim of this study is to evaluate the degree of safety in the
case of omission of prophylaxis antibiotics in clean urologic
operations. Furthermore, confirmation of the degree of
safety could lead to reduction in the cost of treatment as
well as prevent the microorganism’s resistance to
antibiotics.
2. Methods
This study was a double-blind randomized controlled trial in
patients who underwent clean urologic surgery at the
Urology Department, Cipto Mangunkusumo Hospital,
Jakarta, Indonesia, from April 2013 to January 2014. Clean
urologic operations are termed as any urologic operation
with no involvement of the urinary tract, such as circum-
cision, hydrocelectomy, varicocelectomy, orchiectomy,
orchiopexy, percutaneous sperm aspiration, testicular
sperm extraction, genitalia reconstruction, vaso-
epididymostomy, and vasovasostomy. The inclusion criteria
called for individuals who had undergone clean urologic
operations, showed no sign of local infection and systemic
infection prior to the operation, and who had a white blood
cell count (WBC) of 5000e10,000/mL. The exclusion criteria
were as follows: operation involving the urinary or digestive
tract, contaminated or dirty operation site, diabetes mel-
litus, immunodeficiency state, and patients undergoing
immunosuppressant or steroid therapy.Participants were categorized into two groups: one
group with prophylaxis antibiotic therapy (cefazolin, 1 g)
and the second group with placebo (aqua); both drug forms
were given intravenously 30 minutes prior to the surgery.
Randomization was performed using a random number
table, which had been determined before the study star-
ted. Prophylaxis antibiotics or placebo was given by an
anesthesiologist without giving any information to the sur-
geon or to the patients as to which form of therapy had
been administered. One day prior to the operation, hair at
the operative site was shaved off. All patients had povi-
doneeiodine as skin antiseptic prior to the operation.
Evaluation took place after the operation, performed by
the surgeon or ward physician (for inpatients) or by the
clinical physician (for patients already discharged), to
ascertain whether local or systemic infection had occurred.
Local infection included pus, swelling, tenderness, and
wound dehiscence in the operation wound. If such signs
occurred, a culture study for pathogens was conducted.5
The gauze covering the operation wound was removed,
and wound care was performed on Day 7 in the urology
clinic to evaluate local infection. Systemic infection eval-
uation included monitoring of the WBC, body temperature,
and heart rate.9 Local and systemic infections were eval-
uated 1 day and 7 days after the operation. Patients, sur-
geons, ward physicians, and clinical physicians were not
informed if the patients had been administered with pro-
phylaxis antibiotics or placebo. The visual analog scale
(VAS) score, a score ranging from 0 to 10dwhere 0 signifies
no pain and 10 the most severe pain felt by patients, was
also assessed 1 day and 7 days after the operation by a
member of the research team.10
The data were analyzed using the software SPSS17.0
(IBM Inc., New York, United States). Descriptive and anal-
ysis studies were conducted on all participants. Descriptive
study was applied to assess the patients’ characteristics
such as age, sex, diagnosis, type of operation, comorbid-
ities, and local and systemic infection. The analysis study
was conducted to compare the rate of local and systemic
infection between the two groups. Unpaired t test was
applied in variables with normal data distribution; other-
wise, a nonparametric test (ManneWhitney test) was used.
The study had been approved by the Ethics Committee of
the Faculty of Medicine, University of Indonesia, and
informed consent was obtained from all adult participants
and from the parents or legal guardians of children.3. Results
A total of 42 patients participated in this study, of which 21
patients were assigned to the prophylaxis antibiotics (AB)
group and 21 patients to the placebo (P) group. The flow
diagram of the randomization process of the two groups is
shown in Fig. 1.
All patients were male; 14 patients (33.3%) were chil-
dren and 28 patients (66.7%) were adults. The mean age of
adult patients was 42.43  2.36 years and that of young
patients was 6.43  1.51 years. The most frequent diag-
nosis was infertility with azoospermia in 16 patients
(35.6%), treated with percutaneous sperm aspiration and
testicular sperm extraction. Only one patient was
Figure 1 Flow diagram of the randomization process of the two groups.
Table 1 Patients’ characteristics in prophylaxis AB and
placebo groups.






Children 6 (42.9) 8 (57.1) 0.429
Adult 15 (53.6) 13 (46.4)
Diagnosis
Varicocele 6 (66.3) 3 (33.3) 0.841
Azoospermia 8 (50) 8 (50)
UDT 5 (55.6%) 4 (44.4)
Testicular cancer 1 (50) 1 (50)
Prostate cancer 1 (50) 1 (50)
Buried penis 0 (0) 3 (100)




6 (66.7) 3 (33.3) 0.841
PESA/TESE 8 (50) 8 (50)
226 I. Wahyudi et al.diagnosed with hydrocele (2.2%), who later underwent
hydrocelectomy; four patients were diagnosed with malig-
nancy: two patients with testicular cancer (4.4%) treated
with radical orchiectomy and two patients with prostate
cancer (4.4%) treated with bilateral subcapsular orchiec-
tomy. No patients were administered steroid therapy or
presented an immunodeficiency state. There were no sta-
tistical differences in terms of age group (p Z 0.429),
diagnosis (p Z 0.841), or treatment (p Z 0.841). The
characteristics of patients in both groups are shown in
Table 1.
In local infection evaluation, there were no signs of
surgical site infection (pus, swelling, tenderness, or wound
dehiscence) in both groups. Local infection evaluations are
shown in Table 2. There was no statistical difference in
local infection state between the AB prophylaxis (p > 0.99)
and placebo groups (p > 0.99), because all patients in both
groups have no local infection in on Day 1 and Day 7.
In systemic infection evaluation, there was no tachy-
cardia in any of the patients in both groups 1 day and 7 days
after the operation. However, one patient from the placebo
group developed a fever (T Z 38C) 1 day after the oper-
ation. There were no differences in all systemic infection
parameters in both groups, except in WBC (p < 0.005).
Three patients had leukocytosisdone in the prophylaxis
group and two in the placebo group. All of the infections
occurred 7 days after the operation. No other signs of sys-
temic infections were observed in these patients (Table 3).Orchidopexy 5 (55.6) 4 (44.4)
Radical orchiectomy 1 (50) 1 (50)
BSO 1 (50) 1 (50)
Penis reconstruction 0 (0) 3 (100)
Hydrocelectomy 0 (0) 1 (100)
AB Z antibiotics; BSO Z bilateral subcapsular orchiectomy;
PESA Z percutaneous sperm aspiration; TESE Z testicular
sperm extraction; UDT Z undescended testis.4. Discussion
Nowadays, the application of prophylaxis antibiotic therapy
to urology patients has to be carefully considered to
determine clearly the benefits and potential risk factors.
The possible benefits include avoidance of surgical siteinfection, which occurs in 2% of patients undergoing sur-
gery. The possible risks are allergic reaction, development
of microorganisms’ resistance, and incurred costs.1,2,11e13
A recommendation for use of prophylaxis antibiotics
Table 2 Local infection in prophylaxis AB and placebo
groups.






Pus 0 (0.0) 0 (0.0)
Swelling 0 (0.0) 0 (0.0)
Tenderness 0 (0.0) 0 (0.0)
Wound dehiscence 0 (0.0) 0 (0.0) 1
D-7
Pus 0 (0.0) 0 (0.0)
Swelling 0 (0.0) 0 (0.0)
Tenderness 0 (0.0) 0 (0.0)
Wound dehiscence 0 (0.0) 0 (0.0) 1
ABZ antibiotics; D-1Z 1 day after the operation; D-7Z 7 days
after the operation.
Safety of clean urologic operations 227should be based on the type of urologic operation.
Furthermore, prophylaxis antibiotic therapy could be
omitted in clean urologic operations, with the exception of
patients with known risk factors.2,3,14
In this study, postoperation infections were categorized
into two categories: local and systemic infections. All pa-
tients in both groups presented with no local infection 1 day
and 7 days after the operation. Adequate aseptic and
antiseptic techniques, and wound treatment, serve to
prevent local infection without prophylaxis antibiotic
therapy in those patients undergoing clean urologic
operations.2,14e16
In systemic infection monitoring, one patient from the
placebo group presented with fever. The patient, who had
testicular cancer, underwent radical orchiectomy. Although
the patient’s temperature was 38C on Day 1, he showed no
other signs of local or systemic infections. His WBC was
8130/mL at the time of fever. We believe that the cause of
his fever was not an infection but was possibly attributable
to dehydration or systemic inflammatory response syn-
drome. Thus, we continued to observe the patient without
giving him any antibiotics. The fever lasted for 1 day only.
On Day 7, his temperature was 36.1C, and his WBC was
9460/mL.
There were three patients (7.1%) who presented with
increasing WBC (with the highest WBC of 15,930/mL in theTable 3 Systemic infection in prophylaxis AB and placebo grou
Parameter Prophylactic AB (mean 
WBC D-7 (/mL) 6783.81  327.10
Body temperature D-1 (C) 36.31  0.07
Body temperature D-7 (C) 36.25  0.13
Heart rate D-1 (/min) 80.76  2.31
Heart rate D-7 (/min) 82.67  2.31
VAS D-1 2.24  0.41
VAS D-7 0.19  0.13
AB Z antibiotics; D-1 Z 1 day after the operation; D-7 Z 7 days aft
scale; WBC Z white blood cell count; * Z statistically significant.placebo group) 7 days after the operation; however, there
were no signs of local or other systemic infections in these
patients. There was a significant difference in mean WBC
between the two groups (p < 0.005), with a lower mean in
the prophylaxis AB group. This could be due to the pro-
phylaxis antibiotic therapy, resulting in reduced pathogen
microorganisms and a lower WBC in this particular group.
Local and systemic infections often result in pain, and in
those cases, the postoperative pain was also evaluated by
measuring VAS. VAS was low in both groups 1 day after the
operation and even lower 7 days after the operation. No
patient presented with increasing VAS in either group 7 days
after the operation.
Although several international surgeons are not in favor
of antibiotic prophylaxis in clean urologic operations, there
are still only a few studies to date, especially double-blind
randomized controlled trials that compare prophylaxis an-
tibiotics and placebo.1,2 Many available studies were large-
scale retrospective studies reporting on surgical site in-
fections in clean urologic operations without antibiotic
prophylaxis. A study by Yamamoto et al3 found low surgical
site infection rates after 227 laparascopic and 177 open
clean urologic surgeries (1.3% and 1.1%). Fahlenkamp et al17
found a low incidence rate of surgical site infections (0.8%)
after 2407 clean laparoscopic urologic surgeries. Another
large retrospective study was carried out by O’Connor
et al,16 and also by Richardson and Nagler,18 who reported
low rates of wound infection (<0.2% and 0.01%, respec-
tively) in microsurgical varicocelectomy without prophy-
laxis antibiotics. A controlled trial study by Yoshida et al19
found no difference between prophylaxis antibiotics and
placebo in the occurrence of surgical site infections after
minimal invasive surgery to remove renal and adrenal tu-
mors. To date, there is no study that compares the signs of
systemic infection (temperature, heart rate, and WBC) and
VAS between the two groups in clean urologic operations.
The EAU recommendation for clean urologic operations
mentioned no indication for antibiotic prophylaxis in clean
urologic surgery, although there is no clear urologic evi-
dence for this recommendation apart from the lines of
evidence taken from the general surgical literature.1 The
AUA recommendation was also similar to the EAU recom-
mendation, which is to give prophylaxis antibiotics only to
patients with existing risk factors who are undergoing clean
urologic operations.2 In our study, those patients were
excluded, hence there was no bias. The result of the study
was concurrent with EAU and AUA recommendations.ps.
SD) Placebo (mean  SD) p
8578.10  475.46 0.003*
36.23  0.13 0.40
36.29  0.09 0.80
87.43  1.69 0.02
84.38  2.11 0.58
2.52  0.19 0.32
0.14  0.08 0.73
er the operation; SD Z standard deviation; VAS Z visual analog
228 I. Wahyudi et al.This study confirms that clean urologic operations can be
safely applied to urologic patients without the need for
prophylaxis antibiotic therapy in our setting.
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